EANM 视角:精神分裂症谱系障碍的临床 PET 与 SPECT 显像——纵向研究的系统综述
该系统综述检索 PubMed、Embase、Web of Science 和 Cochrane 图书馆数据库至 2024 年 2 月,纳入 56 项纵向研究、共 1329 例患者,中位随访 3 个月,评估 PET 或 SPECT 在精神分裂症谱系或其他精神病性障碍中的应用。最常研究的系统是多巴胺能传递,其次为脑代谢与脑血流;[18F]FDOPA 在预测高危个体转化和治疗反应方面显示大效应量,[123I]IBZM 或 [11C]raclopride 可用于优化治疗剂量以减少副作用。结论认为分子影像在精神分裂症的实际应用中具有重要前景,但需进一步纵向研究和临床试验验证临床有效性与经济可持续性并探索新应用。
要点
- 纳入 56 项纵向研究、共 1329 例患者,中位随访 3 个月,多数使用 PET 示踪剂。
- [18F]FDOPA 在预测高危个体转化和治疗反应方面显示大效应量。
- [123I]IBZM 或 [11C]raclopride 可用于优化治疗剂量以减少副作用。
核心结论
- 分子影像在精神分裂症的实际应用中具有重要前景,其中预测抗精神病药物转化/反应以及改进抗精神病药物剂量管理是两条尤其令人鼓舞的途径。
- 需要进一步的纵向研究和临床试验来验证临床有效性与经济可持续性,并探索新应用。
研究设计与样本
- 系统综述,检索 PubMed、Embase、Web of Science 和 Cochrane 图书馆数据库,检索时间从最早可用日期至 2024 年 2 月。
- 纳入纵向研究,评估 PET 或 SPECT 显像在精神分裂症谱系或其他精神病性障碍个体中的应用。
- 共纳入 56 项研究,合计 1329 例患者,中位随访 3 个月。
- 质量评估使用纽卡斯尔-渥太华量表(NOS)、美国国立卫生研究院(NIH)前后对照研究量表以及 Cochrane 偏倚风险工具第 2 版(Cochrane RoB2)。
- 研究进一步分为三组:临床前与诊断、预测疾病病程或个体化治疗。
主要发现
- 超过三分之二的研究使用 PET 示踪剂,其余研究使用 SPECT 示踪剂。
- 最常研究的系统是多巴胺能传递,其次是脑代谢和脑血流。
- [18F]FDOPA 在预测高危个体转化和治疗反应方面显示大效应量。
- 使用 [123I]IBZM 或 [11C]raclopride 可优化治疗剂量以减少副作用。
局限性
- 需要进一步的纵向研究和临床试验来验证临床有效性与经济可持续性,并探索新应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is a need for biomarkers in psychiatry to improve diagnosis, prognosis and management, and with confirmed value in follow-up care. Radionuclide imaging, given its molecular imaging characteristics, is well-positioned for translation to the clinic. This systematic review lays the groundwork for integrating PET and SPECT imaging in the clinical management of schizophrenia-spectrum disorders. METHODS: Systematic search of PubMed, Embase, Web of Science and Cochrane library databases was conducted from the earliest date available until February 2024. The focus was on longitudinal studies evaluating PET or SPECT imaging in individuals with a schizophrenia-spectrum or another psychotic disorders. Quality assessment was done using the Newcastle-Ottawa Scale (NOS), NIH scale for before-after studies and Cochrane Risk of Bias tool version 2 (Cochrane RoB2). Studies were further categorised into three groups: preclinical and diagnosis, predicting disease course or personalising treatment. RESULTS: Fifty-six studies were included in the systematic review investigating in total 1329 patients over a median of 3 months. Over two-thirds used PET tracers, whereas the remaining studies employed SPECT tracers. The most frequently investigated system was dopaminergic transmission, followed by cerebral metabolism and blood flow. [18F]FDOPA demonstrated large effect size in predicting conversion of subjects at risk and treatment response. Additionally, treatment dosage could be optimised to reduce side effects using [123I]IBZM or [11C]raclopride. CONCLUSION: Molecular imaging holds significant promise for real-life application in schizophrenia, with two particularly encouraging avenues being the prediction of conversion/response to antipsychotic medication and the improved management of antipsychotic dosage. Further longitudinal studies and clinical trials will be essential for validating both the clinical effectiveness and economic sustainability, as well as for exploring new applications.
引用
- Rogeau A, Boer AJ, Guedj E, et al. EANM perspective on clinical PET and SPECT imaging in schizophrenia-spectrum disorders: a systematic review of longitudinal studies. Eur J Nucl Med Mol Imaging. 2024. PMID: 39576337. doi:10.1007/s00259-024-06987-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。